Volagidemab - CISMeF

Preferred Label : Volagidemab;

NCIt definition : A fully human immunoglobulin G2 (IgG2) monoclonal antibody targeting the human glucagon receptor (GCGR), that may be used for the treatment of hyperglycemia. Upon administration, volagidemab specifically targets and binds to GCGR, thereby blocking GCGR signaling. This may inhibit glucagon activity, thereby decreasing hepatic glycogenolysis and gluconeogenesis and ultimately lowering blood glucose levels. Glucagon, a hormone that increases blood sugar, plays an important role in the regulation of blood glucose levels.;

UNII : 77JYS6UZ0M;

CAS number : 1233956-13-2;

Molecule name : REMD 477; REMD-477; AMG-477;

NCI Metathesaurus CUI : CL971997;

Détails

Origin ID

C167005;

UMLS CUI

C5227441;

Currated CISMeF NLP mapping
- Volagidemab [SMS substance]
- volagidemab [MeSH Supplementary Concept]
- volagidemab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- volagidemab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients